A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 - A single institution experience

Metintas M., Ak G., Erginel S., Alatas F., Yildirim H., Kurt E., ...Daha Fazla

LUNG CANCER, cilt.55, sa.3, ss.379-387, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 3
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1016/j.lungcan.2006.11.005
  • Dergi Adı: LUNG CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.379-387
  • Anahtar Kelimeler: mesothelioma, therapy, chemotherapy, best supportive care, prognosis, MULTIMODALITY THERAPY, EUROPEAN-ORGANIZATION, PROGNOSTIC-FACTORS, CANCER-INSTITUTE, PHASE-III, CISPLATIN, COMBINATION, OXALIPLATIN, MITOMYCIN
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

The aim of this study was to investigate the efficacy and safety profile of chemotherapy (CT) compared to best supportive care (BSC) in patients with histopathologically confirmed diffuse malignant pleural mesothelioma (DMPM). A total of 161 patients between 1990 and 2004 treated either with CT (109 patients) or BSC (52 patients) depending on patients choice were evaluated in this analyses. Chemotherapy protocols included a combination of cisplatin, mitomycin C and recombinant interferon alpha 2a (CM-In), or cisplatin, mitomycin C and ifosfamide (CMI), or cisplatin and gemcitabine (CG).